Status and expression of the p16(INK)4 gene in human thyroid tumors and thyroid-tumor cell lines

被引:0
|
作者
Calabro, V
Strazzullo, M
LaMantia, G
Fedele, M
Paulin, C
Fusco, A
Lania, L
机构
[1] UNIV NAPLES FEDERICO II,FAC SCI,DIPARTIMENTO GENET BIOL GEN & MOLEC,I-80134 NAPLES,ITALY
[2] IST NAZL TUMORI FDN PASCLAE,I-80131 NAPLES,ITALY
[3] CTR HOSP LYON SUD,LAB HISTOL & CYTOL,F-69600 OULLINS,FRANCE
[4] UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY
关键词
D O I
10.1002/(SICI)1097-0215(19960703)67:1<29::AID-IJC7>3.0.CO;2-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The p16(INK4) tumor-suppressor gene (also known as CDKN2, CDK41 and MTS1) encodes a negative regulator of the cell cycle. This gene, located in 9p21, is mutated or homozygously deleted in a high percentage of tumor cell lines and specific types of primary tumors. We have examined the status of the p16(INK4) gene in 31 thyroid tumors and 7 thyroid cell liner. No DNA abnormalities were found in primary tumors. Conversely, p16(INK4) gene structural alterations, deletions and point mutations were found in 4 thyroid cell lines. The expression of the 2 different p16(INK4) mRNAs, the p16 alpha and p16 beta transcripts, was determined by RNA-PCR experiments. All the primary thyroid tumors expressed the beta transcript, while the p16 alpha was barely detectable. The thyroid cell lines always expressed the p16 beta transcript, while the a transcript was absent or, whenever present, coded for a mutated form of the p16(INK4) gene product. Taken together, our results suggest that loss of p16(INK4) function is not directly involved in the process of thyroid-tumor development, but it probably gives cells in tissue culture a selective growth advantage. (C) 1996 Wiley-Liss, Inc.
引用
下载
收藏
页码:29 / 34
页数:6
相关论文
共 50 条
  • [1] Abnormalities of the P16(INK4A) gene in thyroid cancer cell lines
    Ivan, M
    WynfordThomas, D
    Jones, CJ
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (13) : 2369 - 2370
  • [2] P16(INK4) MUTATIONS AND ALTERED EXPRESSION IN HUMAN TUMORS AND CELL-LINES
    OKAMOTO, A
    DEMETRICK, DJ
    SPILLARE, EA
    HAGIWARA, K
    HUSSAIN, SP
    BENNETT, WP
    FORRESTER, K
    GERWIN, B
    GREENBLATT, MS
    SERRANO, M
    SHISEKI, M
    YOKOTA, J
    BEACH, DH
    HARRIS, CC
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1994, 59 : 49 - 57
  • [3] High frequency deletion of the tumour suppressor gene P16(INK4a) (MTS1) in human thyroid cancer cell lines
    Jones, CJ
    Shaw, JJ
    Wyllie, FS
    Gaillard, N
    Schlumberger, M
    WynfordThomas, D
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1996, 116 (01) : 115 - 119
  • [4] p16(INK4A) as a human tumor suppressor
    Shapiro, GI
    Rollins, BJ
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1242 (03): : 165 - 169
  • [5] Inactivation patterns of the p16 (INK4α) gene in oral squamous cell carcinoma cell lines
    Akanuma, D
    Uzawa, N
    Yoshida, MA
    Negishi, A
    Amagasa, T
    Ikeuchi, T
    ORAL ONCOLOGY, 1999, 35 (05) : 476 - 483
  • [6] Frequent loss of the P16(INK4 alpha) gene product in human pituitary tumors
    Woloschak, M
    Yu, AQ
    Xiao, JQ
    Post, KD
    CANCER RESEARCH, 1996, 56 (11) : 2493 - 2496
  • [7] Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas
    Elisei, R
    Shiohara, M
    Koeffler, HP
    Fagin, JA
    CANCER, 1998, 83 (10) : 2185 - 2193
  • [8] DELETIONS AND POINT MUTATIONS OF p16,p15 GENE IN PRIMARY TUMORS AND TUMOR CELL LINES
    陶勇浩
    黄倩
    李川源
    Chinese Medical Sciences Journal, 1999, (04) : 9 - 14
  • [9] Expression and characterization of Syrian golden hamster p16, a homologue of human tumor suppressor p16INK4A
    Li, JN
    Qin, DY
    Knobloch, TJ
    Tsai, MD
    Weghorst, CM
    Melvin, WS
    Muscarella, P
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 304 (02) : 241 - 247
  • [10] Deletion and differential expression of p16(INK4a) in mouse lung tumors
    Belinsky, SA
    Swafford, DS
    Middleton, SK
    Kennedy, CH
    Tesfaigzi, J
    CARCINOGENESIS, 1997, 18 (01) : 115 - 120